Recruiting studies: High Risk Smoldering Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · University of Rochester · NCT05597345 Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-
Phase 2 · 1 location(s) · Carl Ola Landgren, MD, PhD · NCT06100237 Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Phase 2 · 2 location(s) · University College, London · NCT06762769 A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment o
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05055063 A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Phase 3 · 2 location(s) · Regeneron Pharmaceuticals · NCT07393282 Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
Phase 2 · 25 location(s) · Stichting European Myeloma Network · NCT06183489 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · 747 location(s) · ECOG-ACRIN Cancer Research Group · NCT03937635 BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06745687 Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
Phase 2 · 1 location(s) · PETHEMA Foundation · NCT06574126 The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Oslo University Hospital · NCT05841550 Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Phase 2 · 3 location(s) · Irene Ghobrial, MD · NCT05469893 Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
Phase N/A · 1 location(s) · University of Utah · NCT06212323 A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple My
Phase 2 · 39 location(s) · Regeneron Pharmaceuticals · NCT06140524 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multipl
Phase 2 · 1 location(s) · Emory University · NCT04776395

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.